Pfizer Says Bivalent COVID-19 Booster Significantly Increases Antibodies to Fight Omicron

New COVID-19 boosters could be authorized by the FDA before full data from human trials are in because of past data on similar vaccines. With the COVID-19 vaccines, there is already a long track record of safety to support the new boosters.

No comments:

Post a Comment